Rezolute, Inc. (RZLT)
4.87
+0.23
(+4.96%)
USD |
NASDAQ |
Oct 09, 16:00
4.86
-0.01
(-0.21%)
After-Hours: 20:00
Rezolute Enterprise Value : 362.63M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 362.63M |
| October 08, 2026 | 340.46M |
| October 07, 2026 | 315.39M |
| October 06, 2026 | 309.61M |
| October 05, 2026 | 310.57M |
| October 02, 2026 | 279.72M |
| October 01, 2026 | 285.51M |
| September 30, 2026 | 292.25M |
| September 29, 2026 | 287.43M |
| September 28, 2026 | 296.11M |
| September 25, 2026 | 269.12M |
| September 24, 2026 | 272.97M |
| September 23, 2026 | 278.76M |
| September 22, 2026 | 282.61M |
| September 21, 2026 | 270.08M |
| September 18, 2026 | 263.33M |
| September 17, 2026 | 273.94M |
| September 16, 2026 | 276.83M |
| September 15, 2026 | 293.22M |
| September 14, 2026 | 302.86M |
| September 11, 2026 | 299.97M |
| September 10, 2026 | 295.15M |
| September 09, 2026 | 284.54M |
| September 08, 2026 | 317.32M |
| September 04, 2026 | 334.67M |
| Date | Value |
|---|---|
| September 03, 2026 | 330.82M |
| September 02, 2026 | 332.74M |
| September 01, 2026 | 326.96M |
| August 31, 2026 | 345.28M |
| August 28, 2026 | 338.53M |
| August 27, 2026 | 373.23M |
| August 26, 2026 | 379.02M |
| August 25, 2026 | 376.13M |
| August 24, 2026 | 376.13M |
| August 21, 2026 | 383.84M |
| August 20, 2026 | 342.38M |
| August 19, 2026 | 348.17M |
| August 18, 2026 | 342.38M |
| August 17, 2026 | 344.31M |
| August 14, 2026 | 336.60M |
| August 13, 2026 | 336.60M |
| August 12, 2026 | 346.24M |
| August 11, 2026 | 338.53M |
| August 10, 2026 | 344.31M |
| August 07, 2026 | 345.28M |
| August 06, 2026 | 346.24M |
| August 05, 2026 | 344.31M |
| August 04, 2026 | 372.27M |
| August 03, 2026 | 366.49M |
| July 31, 2026 | 348.17M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 552.84B |
| Avalo Therapeutics, Inc. | 324.01M |
| Opus Genetics, Inc. | 331.70M |
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.49M |
| Total Expenses (Quarterly) | 20.49M |
| EPS Diluted (Quarterly) | -0.1961 |
| Earnings Yield | -15.33% |
| Normalized Earnings Yield | -15.40 |